ALEXZA Corp.

Nov 19, 09
	NEW STORY
16:15 ET	Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
Nov 09, 09
16:05 ET	Alexza Reports 2009 Third Quarter Financial Results and Updates AZ-004 (Staccato(R) Loxapine) NDA Status
Nov 02, 09
16:30 ET	Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009
Oct 02, 09
09:30 ET	Alexza Pharmaceuticals to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
Sep 30, 09
09:37 ET	Alexza to Raise $19.7 Million in Private Placement
Sep 25, 09
10:05 ET	Alexza Appoints Andrew L. Busser to Board of Directors
Sep 14, 09
07:30 ET	Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
Sep 08, 09
18:00 ET	Alexza Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Aug 26, 09
16:10 ET	Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro
Aug 05, 09
16:10 ET	Alexza Reports 2009 Second Quarter Financial Results and Updates Clinical Pipeline Status
Jul 27, 09
20:28 ET	Alexza to Announce 2009 Second Quarter Financial Results and Update Its Clinical Pipeline Status on Wednesday, August 5, 2009
Jun 15, 09
17:30 ET	Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002
Jun 11, 09
19:52 ET	Alexza's Corporate Presentation to be Webcast at the Piper Jaffray Fourth Annual Europe Conference
May 11, 09
06:15 ET	Alexza's Corporate Presentation to be Webcast at the Eighth Annual JMP Securities Research Conference
May 07, 09
16:10 ET	Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
Apr 30, 09
16:15 ET	Alexza to Announce 2009 First Quarter Financial Results and Update Its Clinical Pipeline Status on Thursday, May 7, 2009
Mar 23, 09
16:15 ET	Alexza's Corporate Presentation to be Webcast at the Future Leaders in the Biotech Industry Conference
Mar 10, 09
16:05 ET	Alexza Reports 2008 Year-End Financial Results and Updates Clinical Pipeline Status
Mar 09, 09
21:10 ET	Alexza's Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference
Mar 06, 09
16:18 ET	Alexza to Announce 2008 Financial Results and Update Its Clinical Pipeline on Tuesday, March 10, 2009
Mar 02, 09
06:00 ET	Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D
Feb 03, 09
16:15 ET	Alexza's Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference
Jan 29, 09
16:05 ET	Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation
Jan 20, 09
17:13 ET	Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
Dec 09, 08
17:26 ET	Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
Nov 11, 08
16:15 ET	Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts
Nov 06, 08
16:05 ET	Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates
Oct 28, 08
09:15 ET	Alexza to Announce 2008 Third Quarter Financial Results and Update Its Clinical Pipeline on Thursday, November 6, 2008
Oct 16, 08
16:05 ET	Alexza Completes Enrollment in Second Phase 3 Clinical Trial With AZ-004 (Staccato(R) Loxapine) for Acute Agitation
Sep 30, 08
16:00 ET	Alexza's Corporate Presentation to be Webcast at the Third Annual JMP Securities Healthcare Focus
Sep 02, 08
16:10 ET	Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
Aug 27, 08
09:00 ET	Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation
Aug 06, 08
16:30 ET	Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Jul 30, 08
19:09 ET	Alexza to Announce 2008 Second Quarter Financial Results and Update Its Clinical Pipeline on Wednesday, August 6, 2008
Jul 24, 08
13:30 ET	Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Jul 09, 08
08:00 ET	Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
Jun 23, 08
08:00 ET	Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
Jun 19, 08
19:03 ET	Alexza's Corporate Presentation to be Webcast at the Piper Jaffray Third Annual Europe Conference
Jun 09, 08
16:10 ET	Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
16:10 ET	Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
May 29, 08
17:38 ET	Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
May 19, 08
18:07 ET	Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.
May 15, 08
18:09 ET	Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality
08:00 ET	Alexza's Corporate Presentation to be Webcast at the Seventh Annual JMP Securities Research Conference and the 2008 Citi Investment Research Global Healthcare Conference
May 12, 08
16:05 ET	Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
May 05, 08
08:00 ET	Alexza to Announce 2008 First Quarter Financial Results and Update Its Clinical Pipeline on Monday, May 12, 2008
May 01, 08
16:15 ET	Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
Apr 30, 08
08:00 ET	Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
Apr 29, 08
08:00 ET	Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
Apr 24, 08
08:00 ET	Alexza's Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Unplugged Conference
Apr 22, 08
21:12 ET	Alexza to Webcast Investor and Analyst Day Presentations
Mar 31, 08
17:00 ET	Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
Mar 26, 08
17:00 ET	Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
Mar 17, 08
16:05 ET	Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
Mar 12, 08
08:30 ET	Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
Mar 07, 08
08:30 ET	Alexza's Corporate Presentation to be Webcast at the Cowen & Company 28th Annual Health Care Conference
Mar 03, 08
08:00 ET	Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
Feb 27, 08
18:00 ET	Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
Feb 25, 08
08:00 ET	Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Feb 05, 08
07:00 ET	Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
Jan 31, 08
08:00 ET	Alexza's Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
Jan 29, 08
07:00 ET	Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexza's Corporate Presentation
Dec 27, 07
16:00 ET	Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
Dec 19, 07
18:00 ET	Alexza Elects Dr. Hal V. Barron to Its Board of Directors
Dec 18, 07
09:00 ET	Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
Nov 21, 07
16:15 ET	19th Annual Piper Jaffray Health Care Conference to Webcast Alexza's Corporate Presentation
Nov 05, 07
06:00 ET	Alexza and Autoliv Announce Commercial Manufacturing and Supply Agreement for Heat Packages Used in Single-Dose Staccato(R) System
Nov 01, 07
16:05 ET	Alexza Reports Third Quarter Financial Results and Updates Development of Product Candidates
Oct 24, 07
16:30 ET	Alexza Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 1, 2007
Oct 23, 07
06:00 ET	Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference to Webcast Alexza's Corporate Presentation
Oct 03, 07
16:15 ET	The 4th Annual BIO Investor Forum to Webcast Alexza's Corporate Presentation
Sep 20, 07
16:10 ET	Robert S. Fishman, MD, FCCP Joins Alexza as Vice President, Medical Affairs
Sep 18, 07
16:37 ET	Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
Aug 13, 07
16:00 ET	Alexza Reports Second Quarter Financial Results and Updates Development of Product Candidates
Aug 06, 07
16:15 ET	Alexza Pharmaceuticals to Announce Second Quarter 2007 Financial Results on August 13, 2007
Jul 18, 07
17:52 ET	Nasrat Hakim Joins Alexza Pharmaceuticals as Vice President, Quality
Jun 22, 07
08:30 ET	Alexza Selected to Join Russell 3000(R) Index
Jun 20, 07
05:30 ET	Alexza Pharmaceuticals Expands Staccato(R) Migraine Product Portfolio
Jun 15, 07
11:00 ET	Piper Jaffray Second Annual London Health Care Conference to Webcast Alexza's Corporate Presentation
Jun 05, 07
09:00 ET	Alexza Pharmaceuticals to Present AZ-004 (Staccato(R) Loxapine) Clinical Data at the Annual NCDEU Meeting
May 31, 07
08:30 ET	Alexza Pharmaceuticals to Present AZ-001 Phase IIb Clinical Data at the American Headache Society Meeting
May 17, 07
16:05 ET	JMP Securities Sixth Annual Research Conference to Webcast Alexza's Corporate Presentation
May 14, 07
16:30 ET	Alexza Selected to Join NASDAQ Biotechnology Index
May 09, 07
16:10 ET	Alexza Reports First Quarter Financial Results and Updates Status of Development Pipeline
May 07, 07
17:37 ET	Alexza to Release First Quarter Results on May 9, 2007
Apr 30, 07
06:00 ET	Alexza Pharmaceuticals Announces Exercise of Over-Allotment Option
Apr 27, 07
08:45 ET	Alexza Pharmaceuticals Announces Pricing of Public Offering of 6,000,000 Shares of Common Stock
Apr 17, 07
16:05 ET	Alexza Pharmaceuticals Announces Public Offering of Common Stock
Mar 30, 07
19:50 ET	Alexza Pharmaceuticals Files Shelf Registration Statement
Mar 26, 07
03:30 ET	Alexza's AZ-001 Phase IIb Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients With Migraine Headache
03:30 ET	Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation
Mar 23, 07
17:53 ET	Alexza to Release Top-Line Results from AZ-001 Phase IIb and AZ-004 Phase IIa Clinical Trials
Mar 14, 07
11:59 ET	Anthony Tebbutt Joins Alexza Pharmaceuticals as Senior Vice President, Corporate Strategy & Business Development
11:53 ET	Jeffrey Williams Named Senior Vice President, Operations & Manufacturing at Alexza Pharmaceuticals
Mar 05, 07
17:00 ET	Cowen & Co. 27th Annual Health Care Conference to Webcast Alexza's Corporate Presentation
Feb 08, 07
16:50 ET	Alexza to Provide Development Pipeline Update and Summary of 2007 Corporate Goals
16:45 ET	Alexza Updates Status of Development Pipeline and Summarizes 2007 Corporate Goals
Feb 06, 07
18:43 ET	BIO CEO & Investor Conference to Webcast Alexza's Corporate Presentation
Jan 18, 07
09:00 ET	Alexza Completes Enrollment in AZ-004 Phase IIa Clinical Trial in Schizophrenic Patients with Acute Agitation
Jan 04, 07
17:00 ET	Alexza Presentation to Be Webcast From the 25th Annual JPMorgan Healthcare Conference
Dec 21, 06
08:30 ET	Alexza Pharmaceuticals Announces Initial Results for the AZ-003 Phase I Clinical Trial
Dec 13, 06
08:00 ET	Alexza Completes Enrollment in AZ-001 Phase IIb Clinical Trial in Patients With Migraine Headaches
Dec 04, 06
08:00 ET	Alexza Pharmaceuticals and Symphony Capital Enter into $50 Million Product Development Collaboration for AZ-002 and AZ-004
Nov 22, 06
12:33 ET	Lazard Capital Markets Third Annual Life Sciences Conference to Webcast Alexza's Corporate Presentation
12:33 ET	Piper Jaffray Health Care Conference to Webcast Alexza's Corporate Presentation
Nov 13, 06
16:15 ET	Alexza Reports Third Quarter Financial Results and Updates Status of Development Pipeline
Nov 09, 06
09:00 ET	JMP Securities Healthcare Sector Focus Conference to Webcast Alexza's Corporate Presentation
Nov 08, 06
09:00 ET	Joseph Baker Joins Alexza Pharmaceuticals as Vice President, Commercial Manufacturing & Global Supply Chain
Nov 03, 06
09:00 ET	Alexza to Release Third Quarter Results on November 13, 2006
Sep 22, 06
08:30 ET	Alexza Initiates Phase IIa Clinical Trial for AZ-004 in Schizophrenic Patients With Acute Agitation
Aug 22, 06
08:00 ET	Michael J. Taylor Joins Alexza Pharmaceuticals as Vice President, Preclinical Development
Aug 10, 06
16:15 ET	Alexza Reports Second Quarter Financial Results and Updates Its Development Pipeline
Aug 03, 06
17:50 ET	Alexza to Release Second Quarter Results on August 10, 2006
Jun 12, 06
19:46 ET	Alexza to Present AZ-001 Phase IIa Clinical Data at the American Headache Society Meeting
Jun 06, 06
19:12 ET	Pacific Growth Equities 2006 Life Sciences Growth Conference to Webcast Alexza's Corporate Presentation
08:00 ET	Alexza Initiates AZ-001 Phase IIb Clinical Trial in Patients With Migraine Headaches
May 15, 06
16:12 ET	Alexza Reports First Quarter Financial Results and Updates Its Development Pipeline
Apr 26, 06
07:00 ET	Alexza Initiates AZ-003 Phase I Clinical Trial
Apr 20, 06
07:00 ET	Alexza Initiates AZ-002 Phase IIa Clinical Trial in Patients With Panic Disorder
Mar 27, 06
11:51 ET	Alexza Pharmaceuticals, Inc. Announces Exercise of Over-Allotment Option
Mar 08, 06
13:13 ET	Alexza Pharmaceuticals, Inc. Sets Price for Initial Public Offering
Dec 22, 05
17:41 ET	Alexza Pharmaceuticals, Inc. Files Registration Statement for Initial Public Offering
Dec 13, 05
10:00 ET	Alexza Pharmaceuticals Expands Executive Management Team
Jul 21, 05
13:00 ET	Alexza MDC Changes Name to Alexza Pharmaceuticals